Cargando…
Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France
OBJECTIVE: This article describes the Personalized Reimbursement Model (PRM) program methodology, limitations, achievement and perspectives in using real-world data of cancer drugs use to improve and personalize drug pricing and reimbursement in France. MATERIALS AND METHODS: PRM platform aggregates...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017943/ https://www.ncbi.nlm.nih.gov/pubmed/35439247 http://dx.doi.org/10.1371/journal.pone.0267242 |
_version_ | 1784688897583742976 |
---|---|
author | Squara, Pierre-Alexandre Luu, Vinh-Phuc Pérol, David Coudert, Bruno Machuron, Valérie Bachot, Camille Samelson, Laurence Florentin, Virginie Pinguet, Jean-Marc Ben Hadj Yahia, Béchir |
author_facet | Squara, Pierre-Alexandre Luu, Vinh-Phuc Pérol, David Coudert, Bruno Machuron, Valérie Bachot, Camille Samelson, Laurence Florentin, Virginie Pinguet, Jean-Marc Ben Hadj Yahia, Béchir |
author_sort | Squara, Pierre-Alexandre |
collection | PubMed |
description | OBJECTIVE: This article describes the Personalized Reimbursement Model (PRM) program methodology, limitations, achievement and perspectives in using real-world data of cancer drugs use to improve and personalize drug pricing and reimbursement in France. MATERIALS AND METHODS: PRM platform aggregates Electronic Pharmacy Records (EPR) data from French medical centers (PRM centers) to build retrospective cohorts of patients treated with injectable cancer drugs in a hospital setting. Data extracted on January 1(st), 2020, from breast cancer (BC) patients who received trastuzumab, trastuzumab emtansin or pertuzumab since January 1st, 2011, and from lung cancer (LC) patients who received bevacizumab or atezolizumab since January 1(st), 2015, enabled recovering their injectable cancer drugs history from diagnosis date until December 30(th), 2019, and served as dataset for assessment. RESULTS: 123 PRM centers provided data from 30,730 patients (25,660 BC and 5,070 LC patients respectively). Overall, 20,942 (82%) of BC and 4,716 (93%) of LC patients were analyzed. Completion rate was above 98% for patients characteristics, diagnostic and treatment related data. PRM centers cover 48% and 33% of BC and LC patients in-hospital therapeutic management in France, respectively. Distribution of BC and LC patients therapeutic management, by medical center category and geographic location, was similar in PRM centers to all French medical centers, ensuring the representativeness of the PRM platform. CONCLUSION: PRM Platform enabled building a national database generating on demand Real-World Evidence based on EPR. This enabled the first performance-based risk-sharing arrangements based on PRM data, between the CEPS and Roche, for atezolizumab cancer immunotherapy in metastatic non-small cell lung cancer indication. |
format | Online Article Text |
id | pubmed-9017943 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-90179432022-04-20 Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France Squara, Pierre-Alexandre Luu, Vinh-Phuc Pérol, David Coudert, Bruno Machuron, Valérie Bachot, Camille Samelson, Laurence Florentin, Virginie Pinguet, Jean-Marc Ben Hadj Yahia, Béchir PLoS One Research Article OBJECTIVE: This article describes the Personalized Reimbursement Model (PRM) program methodology, limitations, achievement and perspectives in using real-world data of cancer drugs use to improve and personalize drug pricing and reimbursement in France. MATERIALS AND METHODS: PRM platform aggregates Electronic Pharmacy Records (EPR) data from French medical centers (PRM centers) to build retrospective cohorts of patients treated with injectable cancer drugs in a hospital setting. Data extracted on January 1(st), 2020, from breast cancer (BC) patients who received trastuzumab, trastuzumab emtansin or pertuzumab since January 1st, 2011, and from lung cancer (LC) patients who received bevacizumab or atezolizumab since January 1(st), 2015, enabled recovering their injectable cancer drugs history from diagnosis date until December 30(th), 2019, and served as dataset for assessment. RESULTS: 123 PRM centers provided data from 30,730 patients (25,660 BC and 5,070 LC patients respectively). Overall, 20,942 (82%) of BC and 4,716 (93%) of LC patients were analyzed. Completion rate was above 98% for patients characteristics, diagnostic and treatment related data. PRM centers cover 48% and 33% of BC and LC patients in-hospital therapeutic management in France, respectively. Distribution of BC and LC patients therapeutic management, by medical center category and geographic location, was similar in PRM centers to all French medical centers, ensuring the representativeness of the PRM platform. CONCLUSION: PRM Platform enabled building a national database generating on demand Real-World Evidence based on EPR. This enabled the first performance-based risk-sharing arrangements based on PRM data, between the CEPS and Roche, for atezolizumab cancer immunotherapy in metastatic non-small cell lung cancer indication. Public Library of Science 2022-04-19 /pmc/articles/PMC9017943/ /pubmed/35439247 http://dx.doi.org/10.1371/journal.pone.0267242 Text en © 2022 Squara et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Squara, Pierre-Alexandre Luu, Vinh-Phuc Pérol, David Coudert, Bruno Machuron, Valérie Bachot, Camille Samelson, Laurence Florentin, Virginie Pinguet, Jean-Marc Ben Hadj Yahia, Béchir Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France |
title | Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France |
title_full | Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France |
title_fullStr | Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France |
title_full_unstemmed | Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France |
title_short | Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France |
title_sort | personalized reimbursement model (prm) program: a real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in france |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017943/ https://www.ncbi.nlm.nih.gov/pubmed/35439247 http://dx.doi.org/10.1371/journal.pone.0267242 |
work_keys_str_mv | AT squarapierrealexandre personalizedreimbursementmodelprmprogramarealworlddataplatformofcancerdrugsusetoimproveandpersonalizedrugpricingandreimbursementinfrance AT luuvinhphuc personalizedreimbursementmodelprmprogramarealworlddataplatformofcancerdrugsusetoimproveandpersonalizedrugpricingandreimbursementinfrance AT peroldavid personalizedreimbursementmodelprmprogramarealworlddataplatformofcancerdrugsusetoimproveandpersonalizedrugpricingandreimbursementinfrance AT coudertbruno personalizedreimbursementmodelprmprogramarealworlddataplatformofcancerdrugsusetoimproveandpersonalizedrugpricingandreimbursementinfrance AT machuronvalerie personalizedreimbursementmodelprmprogramarealworlddataplatformofcancerdrugsusetoimproveandpersonalizedrugpricingandreimbursementinfrance AT bachotcamille personalizedreimbursementmodelprmprogramarealworlddataplatformofcancerdrugsusetoimproveandpersonalizedrugpricingandreimbursementinfrance AT samelsonlaurence personalizedreimbursementmodelprmprogramarealworlddataplatformofcancerdrugsusetoimproveandpersonalizedrugpricingandreimbursementinfrance AT florentinvirginie personalizedreimbursementmodelprmprogramarealworlddataplatformofcancerdrugsusetoimproveandpersonalizedrugpricingandreimbursementinfrance AT pinguetjeanmarc personalizedreimbursementmodelprmprogramarealworlddataplatformofcancerdrugsusetoimproveandpersonalizedrugpricingandreimbursementinfrance AT benhadjyahiabechir personalizedreimbursementmodelprmprogramarealworlddataplatformofcancerdrugsusetoimproveandpersonalizedrugpricingandreimbursementinfrance |